BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li M, Rao C, Pei D, Wang L, Li Y, Gao K, Wang M, Wang J. Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-α, shows antitumor effect in vitro and in vivo. Cancer Cell Int 2014;14:8. [PMID: 24467885 DOI: 10.1186/1475-2867-14-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Lu L, Feng P, Yu M, Chen M, Lin AJ, Chen JL, Yu LH. Current utilization of interferon alpha for the treatment of coronavirus disease 2019: a comprehensive review. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hauptstein N, Meinel L, Lühmann T. Bioconjugation strategies and clinical implications of Interferon-bioconjugates. Eur J Pharm Biopharm 2022:S0939-6411(22)00027-3. [PMID: 35149191 DOI: 10.1016/j.ejpb.2022.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, Liu S, Qu H, Liu S, Wang L, He G, Gong Z. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. Int J Clin Pharm 2020;42:837-45. [PMID: 32410206 DOI: 10.1007/s11096-020-01031-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
4 Zhu S, Huang Y, Tang W, Nussler AK, Zheng F. Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients' Retrospective Study. Front Med (Lausanne) 2020;7:575439. [PMID: 33282889 DOI: 10.3389/fmed.2020.575439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mousavi SM, Hashemi SA, Parvin N, Gholami A, Ramakrishna S, Omidifar N, Moghadami M, Chiang WH, Mazraedoost S. Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial. Drug Metab Rev 2021;53:141-70. [PMID: 33138652 DOI: 10.1080/03602532.2020.1845201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hu X, Hu C, Zhong P, Wen Y, Yang Y, Chen J, Chen X. Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China. Dose Response 2020;18:1559325820949740. [PMID: 32855629 DOI: 10.1177/1559325820949740] [Reference Citation Analysis]
7 Zheng F, Zhou Y, Zhou Z, Ye F, Huang B, Huang Y, Ma J, Zuo Q, Tan X, Xie J, Niu P, Wang W, Xu Y, Peng F, Zhou N, Cai C, Tang W, Xiao X, Li Y, Zhou Z, Jiang Y, Xie Y, Tan W, Gong G. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. Int J Infect Dis 2020;99:84-91. [PMID: 32758689 DOI: 10.1016/j.ijid.2020.07.053] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
8 Qu J, Li GH, Wang JJ, He GF, Huang JJ, Chen Y, Qu Q, Chen XY, Lu Q. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19. Clin Exp Pharmacol Physiol 2021;48:203-10. [PMID: 33090501 DOI: 10.1111/1440-1681.13425] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]